Acute intake of Cargill’s postbiotic EpiCor rapidly alters immune markers

New clinical research suggests that a single dose of Cargill’s yeast-derived postbiotic EpiCor may rapidly modulate immune markers, inflammatory cytokines, and immune cell activity within hours of intake in healthy adults. A randomized placebo-controlled trial found targeted changes in immune signaling, gut–immune pathways, and inflammatory responses, supporting further investigation of EpiCor’s role in acute immune modulation and long-term health benefits.